Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Tricida Trading Down 0.8 %
Shares of Tricida stock traded down $0.11 on Friday, reaching $13.36. The company had a trading volume of 317,270 shares, compared to its average volume of 436,475. The company has a debt-to-equity ratio of 584.92, a current ratio of 5.11 and a quick ratio of 5.11. The firm has a market cap of $743.74 million, a price-to-earnings ratio of -4.93 and a beta of 0.68. Tricida has a 1 year low of $3.84 and a 1 year high of $13.79. The firm's 50-day moving average price is $10.44 and its two-hundred day moving average price is $9.63.
Wall Street Analysts Forecast Growth
Separately, The Goldman Sachs Group dropped their target price on shares of Tricida from $22.00 to $16.00 and set a "buy" rating on the stock in a research note on Tuesday, May 24th.
Insider Activity
In related news, major shareholder Venrock Healthcare Capital Par purchased 91,506 shares of the business's stock in a transaction dated Monday, June 6th. The shares were acquired at an average cost of $9.35 per share, for a total transaction of $855,581.10. Following the acquisition, the insider now owns 5,865,160 shares of the company's stock, valued at approximately $54,839,246. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Tricida news, major shareholder Brian M. Isern sold 37,339 shares of the stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $13.42, for a total transaction of $501,089.38. Following the transaction, the insider now owns 732,675 shares in the company, valued at $9,832,498.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Venrock Healthcare Capital Par acquired 91,506 shares of the business's stock in a transaction on Monday, June 6th. The shares were purchased at an average price of $9.35 per share, with a total value of $855,581.10. Following the completion of the purchase, the insider now owns 5,865,160 shares in the company, valued at approximately $54,839,246. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 999,004 shares of company stock valued at $9,517,079. Corporate insiders own 35.60% of the company's stock.